Literature DB >> 31533942

The Influence of Metabolic Syndrome on the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Infection in Mainland China.

Yifei Tan1, Xiaoyun Zhang1, Wei Zhang1, Li Tang2, Hanwei Yang3, Ke Yan4, Li Jiang1, Jian Yang1, Chuan Li1, Jiayin Yang5, Tianfu Wen5, Huairong Tang6, Lunan Yan1.   

Abstract

BACKGROUND: The association between metabolic syndrome (MS), both in terms of its components and as a whole, and the risk of hepatocellular carcinoma (HCC) in subjects with hepatitis B virus (HBV) infection remains unclear, especially in mainland China.
METHODS: We prospectively included 6,564 individuals with HBV infection from an initial cohort of 105,397 civil servants. The multivariate-adjusted HR and 95% confidence interval (95% CI) were evaluated using Cox proportional hazards models to explore the potential connection between HCC risk and MS. Cumulative incidences were plotted using Kaplan-Meier curves.
RESULTS: After a 45,668.0 person-year follow-up (76.0 ± 30.8 months) of 6,564 subjects who were seropositive for hepatitis B surface antigen, 89 incident HCC cases were identified. MS as a whole was independently associated with a 2-fold increased HCC risk (HR, 2.25; 95% CI, 1.41-3.60) after adjusting for age (in 1-year increments), gender, cigarette smoking, alcohol consumption, liver cirrhosis, and elevated aspartate aminotransferase levels (≥40 U/L). Subjects with three or more factors and those with one or two factors had adjusted increased HCC risks of 2.12-fold (95% CI, 1.16-3.89) and 1.28-fold (95% CI, 0.74-2.22), respectively, in comparison with those without any metabolic factors. Central obesity and type 2 diabetes were associated with significantly increased HCC risk, whereas this association was not observed in obese subjects (body mass index ≥30 kg/m2; 95% CI, 0.73-3.44).
CONCLUSIONS: MS as a whole, central obesity, and type 2 diabetes were independently associated with increased HCC risk in a population with HBV infection in mainland China. IMPACT: MS may be a risk factor for HCC. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 31533942     DOI: 10.1158/1055-9965.EPI-19-0303

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  10 in total

1.  Sarcopenia defined by psoas muscle index independently predicts long-term survival after living donor liver transplantation in male recipients.

Authors:  Yifei Tan; Ting Duan; Bo Li; Bohan Zhang; Yunfeng Zhu; Ke Yan; Jiulin Song; Tao Lv; Jian Yang; Li Jiang; Jiayin Yang; Tianfu Wen; Lunan Yan
Journal:  Quant Imaging Med Surg       Date:  2022-01

Review 2.  Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma.

Authors:  Tracey G Simon; Andrew T Chan
Journal:  Clin Liver Dis       Date:  2020-08-25       Impact factor: 6.126

3.  High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities.

Authors:  Jan-Hendrik Bockmann; Matin Kohsar; John M Murray; Vanessa Hamed; Maura Dandri; Stefan Lüth; Ansgar W Lohse; Julian Schulze-Zur-Wiesch
Journal:  Microorganisms       Date:  2021-04-30

4.  Association between metabolic syndrome and 13 types of cancer in Catalonia: A matched case-control study.

Authors:  Tomàs López-Jiménez; Talita Duarte-Salles; Oleguer Plana-Ripoll; Martina Recalde; Francesc Xavier-Cos; Diana Puente
Journal:  PLoS One       Date:  2022-03-04       Impact factor: 3.240

Review 5.  Hepatocellular Carcinoma in Hepatitis B Virus-Infected Patients and the Role of Hepatitis B Surface Antigen (HBsAg).

Authors:  Satinder P Kaur; Arslan Talat; Hamidreza Karimi-Sari; Andrew Grees; Hao Wei Chen; Daryl T Y Lau; Andreea M Catana
Journal:  J Clin Med       Date:  2022-02-21       Impact factor: 4.241

6.  The Effect of Metabolic Syndrome on the Outcome of Hepatitis B-Associated Hepatocellular Carcinoma Patients After Hepatectomy: A Multicenter Study.

Authors:  Junlong Dai; Xinrui Zhu; Junyi Shen; Yu Zhang; Fei Xie; Yu Yu; Kangyi Jiang; Tianfu Wen; Chuan Li
Journal:  Front Oncol       Date:  2022-03-09       Impact factor: 6.244

7.  Evaluation of the Hepatocellular Carcinoma Predictive Scores PAGE-B and mPAGE-B among Brazilian Patients with Chronic Hepatitis B Virus Infection.

Authors:  Ana Caroline Ferreira da Silva; Marlone Cunha-Silva; Tiago Sevá-Pereira; Daniel F Mazo
Journal:  Viruses       Date:  2022-09-05       Impact factor: 5.818

8.  Prognostic and clinicopathological significance of PD-1 expression in hepatocellular carcinoma: a meta-analysis.

Authors:  Qian Zhang; Kexiang Zhou; Wei Liang; Wei Xiong
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

9.  Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis.

Authors:  Cori Campbell; Tingyan Wang; Anna L McNaughton; Eleanor Barnes; Philippa C Matthews
Journal:  J Viral Hepat       Date:  2020-12-28       Impact factor: 3.517

10.  Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China.

Authors:  Yebei Liang; Hongli Chen; Yuexing Liu; Xuhong Hou; Li Wei; Yuqian Bao; Chunguang Yang; Geng Zong; Jiarui Wu; Weiping Jia
Journal:  J Clin Endocrinol Metab       Date:  2022-01-01       Impact factor: 5.958

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.